Rigel’s ITP Drug Fostamatinib Enters Phase 3 Clinical Trial in Japan
Category: #health  By Pankaj Singh  Date: 2019-09-25
  • share
  • Twitter
  • Facebook
  • LinkedIn

Rigel’s ITP Drug Fostamatinib Enters Phase 3 Clinical Trial in Japan

Chronic immune thrombocytopenia (ITP) is a disorder in which the body’s immune system destroys platelets which play a key role in blood clotting and healing. Currently, therapies such as steroids and splenectomy are used to treat ITP. However, patients are not adequately treated with such therapies, thus arising the need for alternative ITP treatment options.

Some advances were made in this field recently when Rigel Pharmaceuticals Inc., a clinical-stage biotechnology company, announced that its partner firm Kissei Pharmaceuticals Co. Ltd., initiated a Phase 3 trial of fostamatinib disodium hexahydrate for treatment of chronic immune thrombocytopenia (ITP) in adult patients.

According to reports, the safety and efficacy of the orally processed drug will be determined by comparing it with placebo in a randomized, double-blind study. Under the brand name TAVALISSE®, fostamatinib is commercially available in the U.S. and is used for treating patients who are suffering from chronic ITP.

Sources claim that the outcomes of this trial will be applied for supporting a new drug application (NDA) which the company is planning to file in late 2021 or early 2022 in Japan. Presently, the European Medicines Agency is reviewing the marketing authorization application for fostamatinib in chronic ITP in adult patients for potential approval in Europe.

For a record, Kissei is a pharmaceutical company in Japan which focuses on patients' unmet medical needs by collaborating with partners as well as by research, development and commercialization. Previously, Kissei offered a Phase 3 trial design to Pharmaceuticals and Medical Devices Agency (PMDA) of Japan and was recently accepted by the agency.

In 2018, Kissei and Rigel collaborated for the commercialization and development of fostamatinib in all current and potential indications in China, Japan, the Republic of Korea and Taiwan.

According to reports, Rigel, under the terms of the deal, received an upfront cash payment of $33 million, with an additional potential for $147 million in commercial and development milestone payment. The company would also receive payments of product transfer price in the range between mid to upper 20% range depending on tiered net sales.

Source Credit – https://ir.rigel.com/news-releases/news-release-details/rigels-fostamatinib-enters-phase-3-clinical-trial-japan-kissei

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Pankaj Singh    

Pankaj Singh

With an experience as an insurance underwriter and a freelance writer under his belt, Pankaj Singh boasts of quite some expertise in the field of content creation. A qualified Post Graduate in Management, Pankaj has also completed a detailed course in Digital Marketin...

Read More

More News By Pankaj Singh

Bettervest invests in Oakridge Rooftops to support solar projects
Bettervest invests in Oakridge Rooftops to support solar projects
By Pankaj Singh

Oakridge Rooftops Pvt. Ltd., a solar energy company based in India, has reportedly secured funding from Germany-based crowdfunding platform, Bettervest Gmbh. The solar firm has raised the funding for urban solar projects in New Delhi. Oakridge CEO, ...

Databricks buys 8080 Labs to boost its low code/no code offerings
Databricks buys 8080 Labs to boost its low code/no code offerings
By Pankaj Singh

California-based enterprise software company- Databricks has acquired German software startup 8080 Labs that developed bamboolib- a leading GUI for the Python-based Pandas data analysis and manipulation system. The purchase of 8080 Labs makes the fi...

Google rolls out GNI Advertising Lab for news publishers in India
Google rolls out GNI Advertising Lab for news publishers in India
By Pankaj Singh

American tech giant, Google LLC has recently announced the launch of Google News Initiative (GNI) Advertising Lab program for supporting small and medium-sized news publishers that generate original and accurate news for regional and local communitie...